Development of topical ophthalmic In Situ gelforming estradiol delivery system intended for the prevention of age-related cataracts
The goal of this study was to develop and characterize an ion-activated in situ gel-forming estradiol (E2 ) solution eye drops intended for the prevention of age-related cataracts. Accordingly, in situ gelling eye drops were made using gellan gum as an ion-activated gelforming polymer, polysorbate-80 as drug solubilizing agent, mannitol as tonicity agent, and combination of potassium sorbate and edetate disodium dihydrate (EDTA) as preservatives. The formulations were tested for the following characteristics: pH, clarity, osmolality, antimicrobial efficacy, rheological behavior, and in vitro drug release. Stability of the formulation was also monitored for 6 months at multiple storage conditions per ICH Q1A (R2) guidelines. The solution eye drops resulted in an in-situ phase change to gel-state when mixed with simulated tear fluid (STF). The gel structure formation was confirmed by viscoelastic measurements. Drug release from the gel followed non-fickian mechanism with 80% of drug released in 8 hr. The formulations were found to be clear, isotonic with suitable pH and viscoelastic behavior and stable at accelerated and long-term storage conditions for 6 months. In vitro results suggest that the developed formulation is suitable for further investigation in animal models to elucidate the ability of estrogen to prevent and delay cataracts.
Kotreka, U., Davis, V., & Adeyeye, M. (2017). Development of topical ophthalmic In Situ gelforming estradiol delivery system intended for the prevention of age-related cataracts. PLoS ONE, 12 (2). https://doi.org/10.1371/journal.pone.0172306